| Health condition | Total, no. (%)* n = 2273 | Age group, no. (%)* | Aboriginal ancestry, no. (%)* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 50 yr n = 1970 | ≥ 50 yr n = 302 | φc value | Aboriginal n = 496 | Non-Aboriginal n = 1774 | φc value | |||||||
| Central nervous system | ||||||||||||
| Head injury | 738 | (34.1) | 648 | (34.6) | 90 | (30.7) | 0.03 | 193 | (43.0) | 543 | (31.7) | 0.10† |
| Seizures | 92 | (4.3) | 75 | (4.0) | 17 | (5.8) | 0.03 | 23 | (5.1) | 68 | (4.0) | 0.02 |
| Spinal injury | 56 | (2.6) | 47 | (2.5) | 9 | (3.1) | 0.01 | 13 | (2.9) | 43 | (2.5) | 0.01 |
| Musculoskeletal system | ||||||||||||
| Back pain | 411 | (19.3) | 332 | (18.0) | 79 | (27.5) | 0.08 | 73 | (16.4) | 338 | (20.0) | 0.04 |
| Arthritis | 177 | (8.3) | 122 | (6.6) | 55 | (19.2) | 0.16† | 36 | (8.1) | 140 | (8.3) | 0.003 |
| Osteoporosis | 9 | (0.4) | 6 | (0.3) | 3 | (1.1) | 0.04 | 2 | (0.5) | 7 | (0.4) | 0.002 |
| Respiratory system | ||||||||||||
| Asthma | 318 | (14.7) | 284 | (15.1) | 34 | (11.6) | 0.03 | 57 | (12.7) | 261 | (15.2) | 0.03 |
| Bronchitis | 63 | (2.9) | 55 | (2.9) | 8 | (2.7) | 0.004 | 14 | (3.1) | 49 | (2.9) | 0.01 |
| Other pulmonary disease | 38 | (1.8) | 23 | (1.2) | 15 | (5.1) | 0.10† | 3 | (0.7) | 35 | (2.0) | 0.04 |
| Cardiovascular system | ||||||||||||
| Hypertension | 184 | (8.5) | 114 | (6.1) | 70 | (23.8) | 0.22† | 35 | (7.8) | 149 | (8.7) | 0.01 |
| Elevated cholesterol | 114 | (5.3) | 64 | (3.4) | 50 | (17.1) | 0.21† | 11 | (2.4) | 103 | (6.0) | 0.06 |
| Heart attack | 44 | (2.0) | 24 | (1.3) | 20 | (6.8) | 0.13† | 9 | (2.0) | 35 | (2.0) | 0.001 |
| Arrhythmia | 34 | (1.6) | 26 | (1.4) | 8 | (2.7) | 0.04 | 6 | (1.3) | 28 | (1.6) | 0.01 |
| Angina | 30 | (1.4) | 12 | (0.6) | 18 | (6.1) | 0.16† | 5 | (1.1) | 25 | (1.5) | 0.01 |
| Stroke | 16 | (0.7) | 8 | (0.4) | 8 | (2.7) | 0.09 | 2 | (0.4) | 14 | (0.8) | 0.02 |
| Blood-borne virus | ||||||||||||
| HIV/AIDS | 27 | (1.3) | 23 | (1.3) | 4 | (1.5) | 0.005 | 10 | (2.4) | 17 | (1.1) | 0.05 |
| HCV | 191 | (9.4) | 156 | (8.8) | 35 | (12.7) | 0.05 | 66 | (15.5) | 124 | (7.7) | 0.11† |
| Endocrine system | ||||||||||||
| Diabetes | 88 | (4.2) | 54 | (2.9) | 34 | (11.9) | 0.15† | 16 | (3.6) | 72 | (4.3) | 0.01 |
| Gastrointestinal system | ||||||||||||
| Ulcers | 69 | (3.2) | 56 | (3.0) | 13 | (4.4) | 0.03 | 12 | (2.7) | 57 | (3.3) | 0.02 |
| Reproductive system | ||||||||||||
| Prostate problems | 60 | (2.8) | 26 | (1.4) | 34 | (11.8) | 0.21† | 11 | (2.5) | 49 | (2.9) | 0.01 |
| Any cancer history | 39 | (1.8) | 19 | (1.0) | 20 | (6.8) | 0.15† | 4 | (0.9) | 35 | (2.0) | 0.04 |
Note: HCV = hepatitis C virus. *The denominator varies by condition owing to missing data. †Value indicates a meaningful effect size (i.e., at least a weak association). Cramér’s phi (denoted as φc) values between 0.10 and 0.20 indicate a weak association, between 0.20 and 0.40 a moderate association, between 0.40 and 0.60 a strong association and above 0.60 a very strong association.